Trials / Completed
CompletedNCT01958918
Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD
A 12-month, Phase IV, Randomized, Open Label, Multicenter Study to Compare Efficacy of 0.5 mg Ranibizumab Pro re Nata (PRN) Versus 2 mg Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability Till Month 6 of Treatment and Explore Functional Outcomes up to Month 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 712 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to compare the efficacy of 0.5 mg ranibizumab versus 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability.
Detailed description
Patients attended 14 scheduled study visits during 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab | 0.5 mg intravitreal injection |
| DRUG | Aflibercept | 2 mg intravitreal injection |
Timeline
- Start date
- 2013-10-23
- Primary completion
- 2016-11-22
- Completion
- 2017-05-29
- First posted
- 2013-10-09
- Last updated
- 2019-03-21
- Results posted
- 2019-03-21
Locations
68 sites across 10 countries: Austria, Belgium, Denmark, France, Germany, Netherlands, Norway, Portugal, Sweden, Switzerland
Source: ClinicalTrials.gov record NCT01958918. Inclusion in this directory is not an endorsement.